×
Close
註冊
登入
主页
用户
博客
照片
视频
医学图书S馆
医学图书M馆
医学图书D馆
医学术语
群组
活动
用户工具
用户指南
问答
谁看过我
反馈
语言
English
中文
推广
所有
MeSH descriptor
Mesh Subheading
Mesh Supplementary Concept
Mesh Pharmacological Action
search
搜索
清除所有
MeSH 搜索器
AND
OR
加入MeSH搜索引擎
搜索PubMed论文列
清除所有
Denosumab
A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.
推出的年份: 2016(2004)
副标题
administration and dosage
adverse effects
analysis
biosynthesis
blood
cerebrospinal fluid
chemistry
classification
drug effects
economics
genetics
history
immunology
isolation and purification
metabolism
pharmacokinetics
pharmacology
physiology
poisoning
radiation effects
therapeutic use
toxicity
ultrastructure
urine
树号:
D12.776.124.486.485.114.224.060.782, D12.776.124.790.651.114.224.060.782, D12.776.377.715.548.114.224.200.782
MeSH 单一 ID:
D000069448
进入的组:
Xgeva
AMG 162
Prolia
药理作用*:
Bone Density Conservation Agents
All MeSH Categories
Chemicals and Drugs Category
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
add_circle
Ustekinumab [D12.776.124.486.485.114.224.060.937]
All MeSH Categories
Chemicals and Drugs Category
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
add_circle
Ustekinumab [D12.776.124.790.651.114.224.060.937]
All MeSH Categories
Chemicals and Drugs Category
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
add_circle
Ustekinumab [D12.776.377.715.548.114.224.200.937]
thumb_up
Like
share
分享
favorite
书签
0
0
0
0
0
0
0
留言 (
0
)
gif
登入或註冊以發表你的留言
Modal title
×
Modal title
×
分享
登入
Global News and Health Forum
Join Now!
馬上登入
記住我
忘記密碼?
或者使用
Linkedin
留言 (0)